Press Release FeedGet the RSS feed
Menu

Business Wire

101 Therapeutics to Present Phase 2/3 Data on Macrophage-Targeted, Steroid-Sparing Glucocorticoid 101-PGC-005 at ACR Convergence 2026

Business Wire

Poster 0122 on Sunday, November 8: CD206-targeted dexamethasone prodrug was superior to systemic dexamethasone in a 309-patient randomized trial (HR 2.31; p<0.0001), with no systemic steroid added in the '005 arm; abstract positions '005 as a potential steroid-sparing adjunct to biologic therapy, including in PMR, sJIA, GVHD and incomplete responses to single-cytokine biologics

ENGLEWOOD, N.J., October 20, 2026--101 Therapeutics Ltd. (101TX), a clinical-stage biotechnology company developing macrophage-targeted therapeutics, today announced that an abstract on its lead investigational compound, 101-PGC-005 ('005; designated 101-PIF-GC-005 in the published abstract), a chemically synthesized small-molecule, CD206-targeted dexamethasone prodrug, has been accepted for poster presentation at ACR Convergence 2026, the annual meeting of the American College of Rheumatology (ACR), November 6–11 in Orlando, Florida. The abstract, now published in the ACR Convergence 2026 online program, reports that a three-day course of '005 was superior to systemic dexamethasone in a 309-patient randomized Phase II/III (Phase 2/3) trial, and sets out the rationale for '005 as a potential steroid-sparing adjunct to biologic therapy in rheumatology. Founder and Chief Scientific Officer Michael M. Goldberg, MD, will present the poster and is scheduling meetings with pharmaceutical and biotechnology business development, search-and-evaluation and life-science investment teams during the meeting.

First scientific meeting presentation. ACR Convergence 2026 is the first scientific meeting at which 101 Therapeutics will present '005. The Phase II/III trial was run during the COVID-19 pandemic at six sites in India by an independently funded, privately held company, outside the rheumatology literature, and its results have not previously been presented at a scientific meeting. Poster 0122 is the first opportunity for rheumatologists, pharmaceutical partners and investors to review a targeted glucocorticoid that was compared head-to-head with dexamethasone in a randomized Phase 2/3 trial and was superior.

Presentation details

  • Title: CD206-Targeted Glucocorticoid Delivery as an Adjunct to Biologic Therapy in Macrophage-Driven Autoimmune Disease: Proof-of-Concept Clinical Evidence and a Mechanistic Rationale for Addressing the Residual Inflammatory Burden of Single-Pathway Cytokine Blockade

  • Poster/Abstract: 0122

  • Session: Innate Immunity Poster A

  • Date and time: Sunday, November 8, 2026, 10:30 a.m. to 12:30 p.m. ET

  • Presenter: Michael M. Goldberg, MD, Founder and Chief Scientific Officer, 101 Therapeutics

  • Location: ACR Convergence 2026, Orlando, Florida

  1. ExtelJ.P. Morgan Stays Top of Extel’s All-America Equities Research TableExtel's 55th annual survey reveals J.P. Morgan, BofA Securities and Morgan Stanley as the top US research providers. Jefferies leads the analyst leaderboard with BofA and Evercore tied for second. NEW YORK, October 20, 2026--Extel, the leading provider of market sentiment in the financial industry, has
  2. FinanceNovanta Inc.Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026BOSTON, October 20, 2026--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and John Lesica, Chief Operating Officer of Medical Solutions, are scheduled to p
  3. Fashion & luxuryZOZO Apparel USA, Inc.ZOZOFIT Launches ZOZOFIT Pro, a 3D Body Data Dashboard for Gyms, Studios and ClinicsFrom Client scan to business insights, one dashboard to track measurements, monitor progress, and review client history. No scanning hardware, unlimited client seats, one flat rate SANTA MONICA, Calif., October 20, 2026--ZOZO Apparel USA, Inc., the operator of ZOZOFIT, today announced the general avail
  4. AIEvervaultEvervault Launches Browser Tokens, Enabling Secure Agentic PaymentsAI agents can check out on any merchant web page, independent of all agentic commerce protocols, and without accessing underlying sensitive payment information and credentials LAS VEGAS, October 20, 2026--Evervault today announced the launch of Browser Tokens at Money20/20, giving developers building a
  5. AIAmericans Draw the Human Line on AI in Insurance: Fast on Yes, Human on NoNew Liberate survey of policyholders: nearly half would take a 60-second AI payout, 61% still want a person on every denial and 86% want AI use disclosed SAN FRANCISCO, October 20, 2026--Nearly half of policyholders would take a 60-second AI claim payout over waiting on a person, but 61% want a human t
  6. AIDataVisor Cuts Financial Crime Solution Deployment from Months to Days with Agentic AIVera Code, DataVisor's agentic AI, translates customer requirements into configured, verified solutions — a step-change in time-to-value for fraud and AML teams. LAS VEGAS, October 20, 2026--MONEY20/20 USA -- DataVisor , the real-time AI decisioning platform for fraud and risk prevention, today launche